We are hiring! Click to View Open Positions.

Posters

April 2021

2021 Virtual American Academy of Neurology (AAN) Annual Meeting

A Phase 2 Study to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): Interim Analysis Results

View This Poster

April 2021

American Association for Cancer Research (AACR) Annual Meeting 2021

Development of a Comprehensive Biomarker Strategy to Support the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON

View This Poster

March 2021

2021 MDA Virtual Clinical & Scientific Conference

Apitegromab, a Novel High-Affinity Anti-proMyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis (Presentation)

View This Poster

March 2021

2021 MDA Virtual Clinical & Scientific Conference

Apitegromab, a Novel High-Affinity Anti-Promyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis

View This Poster

January 2021

2021 TGFβ for Immuno-Oncology Drug Development Summit

Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy

View This Poster

November 2020

Society for Immunotherapy of Cancer's (SITC) Annual Meeting

DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor, in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone

View This Poster